Last reviewed · How we verify
(F) RH-V14
RH-V14 is a recombinant human erythropoietin used to stimulate erythropoiesis.
RH-V14 is a recombinant human erythropoietin used to stimulate erythropoiesis. Used for Anemia due to chronic kidney disease, Anemia due to cancer chemotherapy.
At a glance
| Generic name | (F) RH-V14 |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | erythropoiesis-stimulating agent |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
RH-V14 works by binding to the erythropoietin receptor, triggering a cascade of intracellular signaling events that ultimately lead to the production of red blood cells. This is particularly useful in patients with anemia due to chronic kidney disease or other conditions. By stimulating erythropoiesis, RH-V14 helps to increase red blood cell count and alleviate symptoms of anemia.
Approved indications
- Anemia due to chronic kidney disease
- Anemia due to cancer chemotherapy
Common side effects
- Increased risk of thromboembolic events
- Hypertension
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (F) RH-V14 CI brief — competitive landscape report
- (F) RH-V14 updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI